65 completed, 17 unknown, 8 terminated, 2 withdrawn. 39 Phase 4, 15 Phase 3, 10 Not applicable, 8 Phase 1, 7 Phase 2.
Follow Acarbose: new trials by email Literature Review of Acarbose trials Research Report on Acarbose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) Acarbose Tablets - Kidney Cancer | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2025-12-31 | 2026-02-17 | |
| A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes Cofrogliptin, Acarbose - Type 2 Diabetes | Not applicable | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 200 | 2025-10-01 | 2025-09-26 |
| CGM-Guided Acarbose for Painful Diabetic Neuropathy Acarbose 50 mg, Placebo - Diabetes, Diabetes Complications | Phase 1 | Completed | Shifa International Hospital | 170 | 2025-09-01 | 2026-03-03 |
| Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment Canagliflozin group, Sitagliptin, Acarbose - Type 2 Diabetes Mellitus, Cognitive Impairment | Phase 4 | Recruiting | Fudan University | 60 | 2024-08-19 | 2026-07-17 |
| The Efficacy and Tolerability of Acarbose in Healthy Individuals Acarbose Tablets 50mg - Tolerance, Side Effect | Phase 4 | Completed | AgelessRx | 15 | 2022-08-10 | 2023-07-27 |
| Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes Metformin plus pioglitazone, Acarbose - Type 2 Diabetes, Blood Glucose Fluctuation | Phase 3 | Unknown | Nanjing First Hospital, Nanjing Medical University | 50 | 2022-04-10 | 2022-11-29 |
| A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D) BAY81-9783 (Acarbose/Metformin) - Type 2 Diabetes Mellitus | Completed | Bayer | 2000 | 2020-12-21 | 2024-09-23 | |
| Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose Linagliptin, Acarbose - Diabetes Mellitus, Type 2 | Terminated | Boehringer Ingelheim | 85 | 2020-03-04 | 2022-06-23 | |
| Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents Glucophage 500Mg Tablet, Acarbose Tablets, Sitagliptin tablet - Type2 Diabetes Mellitus | Phase 4 | Unknown | Peking Union Medical College Hospital | 180 | 2020-03-02 | 2020-02-27 |
| Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose sitagliptin and acarbose - Type 2 Diabetes | Not applicable | Completed | Nanjing First Hospital, Nanjing Medical University | 60 | 2020-01-30 | 2021-09-05 |
| Bioequivalence Study for Acarbose/Metformin FDC Acarbose/Metformin FDC(BAY81-9783), Glucobay, Glucophage - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Bayer | 24 | 2019-10-14 | 2020-04-13 |
| Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive Alogliptin, Acarbose, Metformin - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 1293 | 2019-06-29 | 2022-04-25 |
| Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy. Liraglutid, Dapagliflozin, Acarbose - Type 2 Diabetes Mellitus, Obesity | Not applicable | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 87 | 2019-05-01 | 2019-05-23 |
| Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Sitagliptin, Acarbose - Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1 | Phase 4 | Unknown | Chinese PLA General Hospital | 300 | 2018-10-01 | 2018-07-27 |
| Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus. Acarbose, Prandial insulin - Gestational Diabetes Mellitus in Pregnancy | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 341 | 2018-07-04 | 2024-07-03 |
| Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients Acarbose, Metformin, Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Bayer | 287 | 2018-03-05 | 2020-08-05 |
| Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30 - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 384 | 2018-01-20 | 2022-04-25 |
| Research of Intensive Metabolic Intervention Before Pregnancy in PCOS Acarbose 100 MG, Exenatide, Orlistat - PCOS, Impaired Glucose Tolerance | Phase 4 | Unknown | RenJi Hospital | 160 | 2018-01-01 | 2017-12-26 |
| A Phase IV Study in Drug-Naive Patients With T2DM in China Dapagliflozin, Acarbose - Type 2 Diabetes Mellitus | Phase 4 | Terminated | AstraZeneca | 304 | 2017-12-15 | 2021-12-07 |
| Study of Acarbose in Longevity Acarbose, Placebo - Aging | Phase 2 | Terminated | Montefiore Medical Center | 28 | 2017-08-30 | 2025-06-24 |
Showing 20 of 94. Sign in to see all of them.
Diabetes Mellitus, Type 2 (58) · Diabetes Mellitus (22) · Glucose Intolerance (7) · Coronary Artery Disease (3) · Hyperglycemia (3) · Insulin Resistance (3) · Obesity (3) · Cardiovascular Diseases (2) · Cognitive Dysfunction (2) · Coronary Disease (2) · Glucose Metabolism Disorders (2) · Polycystic Ovary Syndrome (2) · Acute Coronary Syndrome (1) · Atherosclerosis (1) · Congenital Hyperinsulinism (1)
Bayer (17) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Sanofi (3) · Astellas Pharma Inc (2) · AstraZeneca (2) · Boehringer Ingelheim (2) · GWT-TUD GmbH (2) · Merck Sharp & Dohme LLC (2) · Nanjing First Hospital, Nanjing Medical University (2) · Novartis Pharmaceuticals (2) · RenJi Hospital (2) · Taichung Veterans General Hospital (2) · AgelessRx (1) · Aichi Gakuin University (1) · Assistance Publique - Hôpitaux de Paris (1)
China (29) · United States (11) · Canada (9) · South Korea (8) · Taiwan (6) · Germany (5) · India (5) · Japan (5) · Pakistan (3) · Denmark (2) · Hong Kong (2) · Poland (2) · Algeria (1) · Austria (1) · Bosnia and Herzegovina (1)
Pierre Ernst, MD, MSc (3) · Kenneth M Madden, MD (2) · Tao Tao, MD (2) · Wayne H Sheu, MD, PhD (2) · Ashraf Moini, MD (1) · Bita Eslami, MPH (1) · C.J. Tack, MD, PhD, Prof. of Diabetology (1) · Caroline C Gormsen, M.D. (1) · Dean L Kellogg, Jr, MD, PhD (1)
PMID 10662747, PMID 10857967, PMID 11522720, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12832331, PMID 15066944, PMID 15078674, PMID 15710782, PMID 15738343, PMID 16112958, PMID 16681561, PMID 16801564, PMID 16936159, PMID 17515447, PMID 17515448, PMID 17896294, PMID 18539917, PMID 19064853, PMID 19156626, PMID 19515542, PMID 19656312, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20082624, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 20837887, PMID 20970870, PMID 21366473, PMID 21376417, PMID 21663644, PMID 21813293, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22078152, PMID 22179956, PMID 22311903, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638
K23DK074439 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1)